Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension

Feb.09
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.

 

Key Takeaways

 

  • Data source: US NHANES 2021–2023; 6,262 participants aged >12 with complete smoking/vaping information
  • Prevalence differences: Elevated BP 54.4% vs 39.2%; hypertension 15.4% vs 11.8% (smoking/vaping vs non-use)
  • Adjusted associations: Elevated BP aOR 1.34 (95% CI 1.12–1.60); hypertension aOR 1.46 (95% CI 1.06–1.99)
  • Industry perspective: Provides data that regulators can use when evaluating e-cigarettes

 


 

2Firsts, February 9, 2026

 

A paper titled “Tobacco and Electronic Cigarette Use with Hypertension and the Mediating Effect of Dyslipidemia – The NHANES Study” reports that the study was published on February 6, 2026 in American Journal of Physiology – Heart and Circulatory Physiology. Authors Douglas R. Corsi and Andrew O. Agbaje analyzed data from the US National Health and Nutrition Examination Survey (NHANES) 2021–2023 cycle to assess associations between smoking and/or e-cigarette use and elevated blood pressure and hypertension, and to examine potential mediating pathways.

 

The paper states that the NHANES 2021–2023 cycle included 11,933 participants, and 6,262 individuals aged over 12 with complete smoking/vaping status were included in the analysis. The reference group was “no smoking and no vaping” (n=5,072), and the exposure group was “any smoking and/or vaping” (n=1,190). Elevated blood pressure was defined as ≥120/70 mmHg, and hypertension as ≥140/90 mmHg. Smoking and/or vaping status was obtained via questionnaire, asking whether participants had used e-cigarettes in the past five days and whether they smoked.

 

The paper reports that among the 6,262 participants (mean age 42.2 years; 63.3% female), the prevalence of elevated blood pressure was 54.4% among smokers/vapers versus 39.2% among non-users; the prevalence of hypertension was 15.4% versus 11.8%, respectively.

 

In fully adjusted models, the paper reports an odds ratio of 1.34 (95% CI 1.12–1.60) for elevated blood pressure and 1.46 (95% CI 1.06–1.99) for hypertension associated with smoking/vaping. The paper also reports an association between smoking/vaping and higher diastolic blood pressure (mean difference 1.05 mmHg), with no statistically significant association with systolic blood pressure.

 

From a regulatory perspective, the study uses the latest NHANES nationwide data and reports statistically significant associations between smoking and e-cigarette use and the risks of elevated blood pressure and hypertension, providing new empirical evidence for regulators evaluating the public health impact of nicotine products. The findings indicate that within existing regulatory frameworks, e-cigarettes and patterns of use in combination with conventional tobacco may warrant further consideration in health-risk assessment, product classification management, and monitoring of user populations. The study may also provide a reference basis for future development of e-cigarette regulatory standards, health warning information, and risk communication policies.

 

From a market perspective, the findings may also influence industry participants’ compliance strategies and approaches to risk communication. Against the backdrop of intensified regulation of nicotine products in many jurisdictions, companies may need to place greater emphasis on potential long-term health factors in product design, marketing compliance, and consumer information disclosure. The study’s emphasis on complex use patterns such as “dual use” may also encourage the market to evolve further toward compliance and greater risk transparency.

 

For details of the study, please refer to the original paper.

 

Image source: journals.physiology.org

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company Launches Flavored Vuse Pro Pods in U.S. Without FDA Marketing Authorization
R.J. Reynolds Vapor Company has begun selling four flavored Vuse Pro pods — Peach, Berry, Watermelon and Fresh Mint — in Ohio and selected other U.S. markets. According to the Vuse U.S. FAQ, Vuse Pro contains approximately 5.0% nicotine by weight, and Vuse Pro pre-filled pods are intended for use with Vuse Alto devices. Reynolds told 2Firsts that product labeling lists an e-liquid capacity of 2.0 mL per pod. The Vuse Alto Power Unit received FDA marketing authorization in 2024, while the new Vuse Pro pods themselves have not received marketing granted orders. The rollout follows the FDA’s May 2026 revision of enforcement priorities for certain unauthorized vaping products with qualifying pending applications.
BAT
Sep.10
Product | PMI Launches Airport-Exclusive IQOS Skylens Limited Edition, Expanding From Japan’s Narita to Travel Retail Markets in 13 Countries Summary
Product | PMI Launches Airport-Exclusive IQOS Skylens Limited Edition, Expanding From Japan’s Narita to Travel Retail Markets in 13 Countries Summary
Philip Morris International (PMI) has introduced the airport-exclusive limited-edition IQOS ILUMA i PRIME Skylens, the company’s first device created specifically for airport travel retail. Inspired by the world of flight and finished in metallic blue, Skylens debuted at Narita International Airport in Japan before expanding into selected airport duty-free and travel-retail channels across 13 countries in Europe, Asia, the Middle East and Africa. The product retains the existing IQOS ILUMA i PRIME platform, with differentiation centered on airport exclusivity, design and travel-retail execution rather than a new heating architecture.
PMI
Aug.19
BAT Expands ITC Infotech Partnership Across Poland, Romania and India to Advance AI
BAT Expands ITC Infotech Partnership Across Poland, Romania and India to Advance AI
ITC Infotech has expanded its multi-year strategic technology partnership with British American Tobacco (BAT), providing technology services across Poland, Romania and India while continuing to support BAT's newly launched Future Capabilities Centre in India and existing technology hubs in Malaysia and Mexico. The companies said the agreement will focus on AI-enabled innovation, technology capability building and greater operational efficiency. The partnership also aligns with BAT's broader Fit2Win transformation programme, under which the group is expanding the use of external technology and business-services partners to simplify its global operating model.
Aug.13
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Smoke-Free Business Hits 42% of Q2 Net Revenue as PMI’s First TNFD Report Covers Single-Use Electronics, Critical Raw Materials and IQOS Repairs
Philip Morris International has published its first report aligned with the Taskforce on Nature-related Financial Disclosures, bringing its electronics supply chain and the use and end-of-life stages of smoke-free devices and consumables into its nature-related assessment. PMI said its smoke-free business accounted for about 42% of total net revenues in the second quarter of 2026. The report says non-circular electronic products, particularly single-use items, can increase consumption of limited natural resources and also details an IQOS repair pilot. A 2040 circularity scenario tests assumptions including a 50% reduction in product waste-related costs, 10% raw-material savings and a 25% substitution rate for refurbished products versus new products.
Sep.23
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
Bret Koplow Takes Permanent Charge of FDA Tobacco Center After Pushing Faster PMTA Reviews, as HHS Emphasizes Innovation and Access to Lower-Risk Alternatives
The U.S. Department of Health and Human Services has named Bret Koplow permanent director of the FDA’s Center for Tobacco Products, ending his period as acting chief. Koplow has spent years working on tobacco regulation, law and policy inside the FDA and, while serving as acting director, pushed for faster PMTA reviews and nicotine pouch review pilots. HHS also said CTP will prioritize innovation and access to less harmful alternatives for adult smokers while continuing efforts to protect youth.
Sep.09
Switzerland Tightens Vape Checks as Only 3 of 32 Tested Products Meet New Tobacco Rules
Switzerland Tightens Vape Checks as Only 3 of 32 Tested Products Meet New Tobacco Rules
According to Swiss media outlet Blick, local authorities are strengthening compliance checks on vape products, nicotine pouches and other tobacco-related products following the implementation of Switzerland’s revised Tobacco Products Act. A Basel laboratory tested 32 disposable vapes and e-liquids, with only three meeting regulatory requirements and 21 products banned from sale. Swiss authorities are also expanding retail inspections, laboratory testing and youth purchase checks to enforce the new tobacco and nicotine product rules.
Aug.12